It's been a banner year thus far for ADMA Biologics Inc. (ADMA) whose share price is up an impressive 168% year-to-date.
This fully integrated commercial biopharmaceutical company focuses on the manufacture and marketing of specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its marketed products include the FDA-approved ASCENIV, BIVIGAM and NABI-HB.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.